0001144204-11-019379.txt : 20110401 0001144204-11-019379.hdr.sgml : 20110401 20110401060835 ACCESSION NUMBER: 0001144204-11-019379 CONFORMED SUBMISSION TYPE: NT 10-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20101231 FILED AS OF DATE: 20110401 DATE AS OF CHANGE: 20110401 EFFECTIVENESS DATE: 20110401 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Genesis Biopharma, Inc CENTRAL INDEX KEY: 0001425205 STANDARD INDUSTRIAL CLASSIFICATION: ARRANGEMENT OF TRANSPORTATION OF FREIGHT & CARGO [4731] IRS NUMBER: 753254381 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: NT 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-53127 FILM NUMBER: 11728608 BUSINESS ADDRESS: STREET 1: 1601 N. SEPULVEDA BLVD., #632 CITY: MANHATTAN BEACH STATE: CA ZIP: 90266 BUSINESS PHONE: 866-963-2220 MAIL ADDRESS: STREET 1: 1601 N. SEPULVEDA BLVD., #632 CITY: MANHATTAN BEACH STATE: CA ZIP: 90266 FORMER COMPANY: FORMER CONFORMED NAME: FREIGHT MANAGEMENT CORP DATE OF NAME CHANGE: 20080128 NT 10-K 1 v217216_nt10k.htm Unassociated Document
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SEC FILE NUMBER
000-53127
 
FORM 12b-25
CUSIP NUMBER
37182R102
 
 
NOTIFICATION OF LATE FILING
 
 
(Check One): x Form 10-K ¨ Form 20-F ¨ Form 11-K o Form 10-Q ¨ Form N-SAR ¨ Form N-CSR
 
For Period Ended: December 31, 2010
 
¨ Transition Report on Form 10-K
 
¨ Transition Report on Form 20-F
 
¨ Transition Report on Form 11-K
 
¨ Transition Report on Form 10-Q
 
¨ Transition Report on Form N-SAR
 
For the Transition Period Ended: ___________________
 

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
 
If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates: ________________________________________________________________________
 
 
PART I – REGISTRANT INFORMATION
 
Genesis Biopharma, Inc.
Full Name of Registrant
 
Freight Management Corp.
Former Name if Applicable
 
11500 Olympic Boulevard, Suite 400
Address of Principal Executive Office (Street and Number)
 
Los Angeles, California 90064
City, State and Zip Code

 
PART II – RULES 12b-25(b) AND (c)
 
If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)
 
x
(a)  The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
   
x
(b)  The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, 11-K, Form N-SAR, or N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and
   
o
(c)  The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
 
 
 
 
 
PART III – NARRATIVE
 
State below in reasonable detail the reasons why Form 10-K, 20-F, 11-K, 10-Q, N-SAR, or the transition report or portion thereof, could not be filed within the prescribed time period.
 
Genesis Biopharma, Inc. (the “Company”) is unable to file its Annual Report on Form 10-K (the “Report”) for the fiscal year ended December 31, 2010 by the scheduled filing deadline because of the recent changes in the Company’s management.  A new Chief Executive Officer and new Chief Financial Office were appointed to their respective positions in February 2011, and they require additional time to complete and review the information that needs to be included in the Report.
 
PART IV – OTHER INFORMATION
 
(1)
Name and telephone number of person to contact in regard to this notification
 
Michael Handelman
  
866
  
963-2220
(Name)
  
(Area Code)
  
(Telephone Number)
 
(2)
Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). ý Yes ¨ No
 
 
(3)
Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? ¨ Yes x No
 
If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
 
________________________________________________________________________
 
                    Genesis Biopharma, Inc.                    
(Name of Registrant as Specified in Charter)
 
has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
 
Date:  March 31, 2011
By:
/s/ Michael Handelman  
    Michael Handelman, Chief Financial Officer  
       
 
INSTRUCTION: The form may be signed by an executive officer of the registrant of by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative's authority to sign on behalf of the registrant shall be filed with the form.
 
 
- 2 -